ELEVATED SERUM LEVELS OF IL-17 DURING DISEASE ACTIVITY OF ANKYLOSING SPONDYLITIS: A SYSTEMATIC REVIEW WITH META-ANALYSIS (Atena Editora)

Registro completo de metadados
MetadadosDescriçãoIdioma
Autor(es): dc.contributor.authorCorreia, Maria Andreza Bezerra-
Autor(es): dc.contributor.authorLins, Thiago Ubiratan Lins e-
Autor(es): dc.contributor.authorCavalcanti, Nara Gualberto-
Autor(es): dc.contributor.authorPereira, Michelly Cristiny-
Autor(es): dc.contributor.authorRêgo, Moacyr Jesus Barreto de Melo-
Autor(es): dc.contributor.authorKron-Rodrigues, Meline Rossetto-
Autor(es): dc.contributor.authorMarques, Claudia Diniz Lopes-
Autor(es): dc.contributor.authorPitta, Maira Galdino da Rocha-
Data de aceite: dc.date.accessioned2021-12-02T15:14:29Z-
Data de disponibilização: dc.date.available2021-12-02T15:14:29Z-
Data de envio: dc.date.issued2021-11-16-
Fonte: dc.identifier.urihttp://educapes.capes.gov.br/handle/capes/643661-
Resumo: dc.description.abstractConcentrations of serum IL-17 have been found at high levels in patients with AS. The role of serum IL-17 in ankylosing spondylitis (AS) was investigated through a meta-analysis undertaken to examine the correlation between AS disease activity and serum levels of IL-17 in AS compared to healthy controls and AS patients. Searches were performed in PubMed, ScienceDirect, Cochrane, and Lilacs databases for pertinent case-control studies using with the descriptors “Spondylitis, Ankylosing” and “Interleukin-17”. Expression in relation to healthy controls and correlation of IL-17 with BASDAI were plotted using Review Manager 5.3 software. Quality assessment of each eligible study used the Newcastle-Ottawa Scale. Thirteen case-control studies were selected for this meta-analysis and contained a pooled total of 752 AS patients and 607 healthy controls. Our main result revealed strikingly higher levels of serum IL-17 in AS patients, compared to healthy controls. Pooled mean difference 14.59, pooled risk ratios (RRs) with 95% confidence intervals (CIs) 7.73, 21.45; p<0.00001. Serum IL-17 is highly expressed in serum of patients with AS and is related to disease activity. The treatment in use significantly influenced IL-17; however, we did not observe a significant difference in the expression of IL-17 in the treatment of patients taking anti-TNF, proving that it does not interfere in this pathway.pt_BR
Idioma: dc.language.isoenpt_BR
Palavras-chave: dc.subjectCASE CONTROL STUDIESpt_BR
Título: dc.titleELEVATED SERUM LEVELS OF IL-17 DURING DISEASE ACTIVITY OF ANKYLOSING SPONDYLITIS: A SYSTEMATIC REVIEW WITH META-ANALYSIS (Atena Editora)pt_BR
Tipo de arquivo: dc.typelivro digitalpt_BR
Aparece nas coleções:Livros digitais